Company to leverage new production site to capture growth in China and expand Point of Care and rapid diagnostics offer for both emerging and developed countries
Asia
Europe, Middle East, Africa
North America
bioMérieux Acquires Chinese Rapid Test Manufacturer Meikang BioTech
14 January, 2010
Sepsis and Septic Shock on the Rise, Affecting Younger Patients
11 January, 2010
Physicians Attribute Antimicrobial Resistance and the Spread of Multi-Drug Resistant Organisms (MDRO) to Antibiotic Overuse
Philips and bioMérieux Announce Partnership to Develop and Market Next-Generation Handheld Diagnostic Solutions for Point-of-Care
07 January, 2010
Fully automated handheld diagnostic test devices designed to improve diagnosis and disease management in critical care settings within hospitals.
bioMérieux Launches VIDAS® Free PSA rt BioMarker for Prostate Cancer
05 January, 2010
New test provides physicians with additional information which may eliminate invasive biopsies
bioMérieux Recognized for Outstanding Service in Physician Office Distribution Network
14 December, 2009
bioMérieux, a world leader in the field of in vitro diagnostics, has been named the recipient of the Rising Star Award by National Distribution & Contracting, Inc. (NDC) for its outstanding service and support in the physician office market.
Data from Three Clinical Studies of bioTheranostics' Breast Cancer Molecular Test Presented at CTRC-AACR San Antonio Breast Cancer Symposium
12 December, 2009
Independent studies validate the utility of THEROS BCI® for risk stratification of early stage breast cancer patients and prediction of response to commonly used aromatase inhibitor
Mérieux Alliance Becomes Institut Mérieux
07 December, 2009
Alain Mérieux confirms the Institute’s commitment to meeting new medical and public health challenges
Long-Term Strategic Partnership Between bioMérieux and the CEA to Develop Innovative Technologies for Infectious Disease Management
03 December, 2009
bioMérieux and the CEA (French Atomic Energy Commission) announce today a long-term strategic partnership, intensifying their research collaboration to develop novel technologies for improved infectious disease management.
bioMérieux's TEMPO® Gains Approval for Testing E. Coli in Food Samples
01 December, 2009
pr_tempo_small_thumb19.jpg bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to announce that TEMPO® EC, an automated quality indicator test for the fast enumeration of Escherichia coli in food products, has been granted Official Methods of Analysis (OMA) approval by AOAC INTERNATIONAL. This added level of certification assures TEMPO EC users that the test meets stringent AOAC standards for excellence in indicator testing.
bioMérieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment
17 November, 2009
bioMérieux has signed an agreement with GlaxoSmithKline to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients. This test, based on emerging biomarkers, will be intended for use in both adjuvant and metastatic breast cancer settings, subject to regulatory approvals. Over 500,000 new cases of breast cancer are diagnosed each year in the US and Europe alone and predictive tests have been shown to improve outcomes for these patients.